Abstract
This study suggests that rehabilitation therapy improves the effectiveness of nusinersen on type-2 SMA patients, and the levels of pNF-H and skeletal muscle MRI can serve as potential biomarkers for evaluating the effectiveness of SMA treatment.
Introduction
Spinal Muscular Atrophy (SMA) is a debilitating genetic disorder characterized by the progressive loss of motor neurons, leading to severe muscle wasting. The introduction of Nusinersen (Spinraza), an antisense oligonucleotide that increases functional SMN protein production, has transformed the treatment landscape. However, a critical clinical question remains: does systematic physical rehabilitation provide a synergistic benefit when combined with pharmacological intervention? Furthermore, there is an urgent need for objective biomarkers to complement subjective motor function scales. This study evaluates the impact of combination therapy and the utility of phosphorylated neurofilament heavy chain (pNF-H) and muscle MRI as biomarkers for treatment success.
Methods
The researchers conducted a 14-month observational study involving 22 pediatric patients with genetically confirmed Type 2 SMA at the Children’s Hospital of Nanjing. The cohort was divided into two groups:
- Nusinersen + Rehabilitation: 11 patients received Nusinersen alongside systematic rehabilitation (physical therapy, occupational therapy, respiratory training, and orthotics) at least five times per week.
- Nusinersen Alone: 11 patients received only the pharmacological treatment.
Motor function was tracked using four standardized scales: CHOP-INTEND, HFMSE, RULM, and HINE-2. Objective biomarkers were assessed via ELISA for pNF-H levels in serum and cerebrospinal fluid (CSF). Additionally, T1-weighted MRI of the thigh muscles was performed to evaluate fat infiltration using the modified Mercuri grading system (0–5 scale).
Results
Enhanced Motor Recovery
The study found that while both groups showed improvement, the rehabilitation group achieved significantly higher gains. At the 14-month mark, the combination therapy group demonstrated superior improvements in CHOP-INTEND (p=0.004) and RULM (p=0.009) scores compared to the drug-only group. This suggests that while Nusinersen rescues motor neurons, physical therapy is essential to re-train the musculoskeletal system to utilize that regained potential.
Biomarker Correlation and Early Intervention
A significant negative correlation (r = -0.528, p = 0.014) was observed between the reduction in CSF pNF-H levels and improvements in CHOP-INTEND scores, validating pNF-H as a biological indicator of neuroprotection. The data also reinforced the importance of early intervention; both "medication age" and the "medication time window" were negatively correlated with motor score increases, highlighting that earlier treatment yields better functional outcomes.
MRI and Safety
While muscle fat infiltration is typically difficult to reverse, one patient in the rehabilitation group showed a reduction in fat infiltration (Grade 4 to Grade 3) on MRI, suggesting its potential for tracking long-term structural healing. The combination therapy was well-tolerated, with only minor adverse events related to the lumbar puncture procedure.
Discussion and Conclusion
This study demonstrates a clear "synergy effect" between Nusinersen and systematic rehabilitation in Type 2 SMA patients. The findings support the use of pNF-H as a sensitive "damage meter" for axonal degeneration and suggest that muscle MRI can provide objective evidence of structural changes that clinical scales might miss.
Despite limitations such as a small sample size and a relatively short 14-month observation period, the results advocate for a multidisciplinary approach to SMA treatment. Future multi-center trials with longer follow-up periods are necessary to further refine these biomarkers and optimize personalized therapy for SMA patients.
Summary updated